Two significant systematic reviews of CST research were published in 2024, and both reached broadly sceptical conclusions. For anyone who takes CST seriously — as a practitioner, a client, or someone considering trying it — these reviews deserve honest engagement rather than dismissal or deflection.
At the same time, the full picture of the research is more textured than the headlines suggest. The 2024 reviews matter, and their findings should be taken seriously. They aren't, however, the whole story. Knowing both what they found and the methodological landscape they were navigating helps you hold the evidence with appropriate nuance.
What the 2024 reviews found
Ceballos-Laita and colleagues, publishing in Healthcare (2024), analysed 15 randomised controlled trials and concluded that CST produced no benefits in any of the musculoskeletal or non-musculoskeletal conditions assessed. The conditions included headache disorders, neck pain, low back pain, pelvic girdle pain, and fibromyalgia. The authors' conclusion was direct: the evidence did not support the use of CST for these conditions.
Amendolara and colleagues, publishing in Frontiers in Medicine (2024), took a broader sweep — 24 RCTs including 1,613 participants, across multiple conditions. Their conclusion was similar. CST showed no significant effects in the primary outcome analysis, indicating, in their words, 'a lack of usefulness in patient care.' Both papers are peer-reviewed, published in indexed journals, and conducted by researchers without an obvious axe to grind. The findings can't be dismissed as hostile to complementary medicine.
Why the picture is more complicated
The systematic review format pools data across multiple studies to detect average effects. When individual trials vary widely in quality, populations, therapist training levels, session counts, and outcome measures, the pooled analysis tends to flatten real effects that existed in some conditions but not others.
This is particularly relevant for CST research. The 2024 reviews included trials where therapist training ranged from short Upledger courses to full biodynamic training — studies that were not actually measuring the same intervention. They included studies with as few as four sessions, which most experienced practitioners would say is insufficient for longer-standing conditions. Many of the included trials were rated as high risk of bias. In the Amendolara review, 14 of 24 carried that designation. When the research base is mostly methodologically weak trials, a meta-analysis finding no effect is telling you that weak trials didn't produce clear results — which is somewhat expected.
That's not a defence of CST. It's an observation that the current research base is not yet good enough to definitively answer the question either way.
What more positive evidence looks like
The 2019 chronic pain meta-analysis by Jäkel and von Hauenschild, published before the 2024 reviews, reached notably different conclusions: significant effects of CST on pain and function lasting up to six months, based on the studies available at the time. Not everyone draws the same lessons from that analysis, but it shows how much the conclusions of systematic reviews can shift based on which trials are included and how they're categorised.
Individual condition-specific trials have shown promising results in migraine, neck pain, fibromyalgia, and infant colic. A 2015 RCT on neck pain with 54 patients found significant and clinically relevant effects on pain intensity compared with sham. A 2010 RCT on fibromyalgia with 92 patients showed significant pain reduction. These aren't large trials, and they don't overturn the 2024 reviews. But they suggest that dismissing CST wholesale on the basis of broad negative reviews would miss the more specific picture emerging from individual condition research.
What this means for everyone
For practitioners, the 2024 reviews are a real call to be honest about what the formal evidence currently supports — and to avoid overclaiming. The experience clients report is real, and many people find genuine benefit. But that experience shouldn't be presented as equivalent to proven clinical efficacy in the absence of supporting evidence.
For clients, the honest answer is that the formal research base is mixed. The 2024 reviews found no clear statistical benefit across the conditions studied. Other research has been more encouraging in specific areas. The safety profile of CST is genuinely good. The touch is light, and adverse effects are rare and generally mild. If you're considering it for a condition where other approaches haven't helped, that's a reasonable context in which to try it — with realistic expectations and without dropping other forms of care. The researchers are still learning, and so is the field.
The 2024 meta-analyses are the most comprehensive recent assessment of CST evidence and they deserve to be taken seriously. The picture they present is sobering. It's also incomplete. The most honest position is to hold both at once while the research keeps developing.